HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Longitudinal analysis of a secondary BRCA2 mutation using digital droplet PCR.

Abstract
Development of resistance to platinum and poly(ADP-ribose) polymerase inhibitors via secondary BRCA gene mutations that restore functional homologous recombination has been observed in a number of cancer types. Here we report a case of somatic BRCA2 mutation in a patient with high grade serous ovarian carcinoma. A secondary mutation predicted to restore the BRCA2 open reading frame was detected at low frequency (2.3%) in whole exome sequencing of a peritoneal biopsy at disease progression after treatment that included carboplatin and olaparib. We used digital droplet PCR (ddPCR) to verify the presence and frequency of this mutation in the biopsy sample at progression and also used this approach to assess the presence of the secondary mutation in preceding biopsies at diagnosis and first relapse. We found no evidence for the secondary mutation being present prior to the final progression biopsy, suggesting that this mutation was acquired late in the course of treatment. ddPCR provides a sensitive and specific technique to investigate the presence of low frequency mutations in a time series of biopsies.
AuthorsSaira Khalique, Stephen J Pettitt, Ger Kelly, Nina Tunariu, Rachael Natrajan, Susana Banerjee, Christopher J Lord
JournalThe journal of pathology. Clinical research (J Pathol Clin Res) Vol. 6 Issue 1 Pg. 3-11 (01 2020) ISSN: 2056-4538 [Electronic] England
PMID31577852 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2019 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland and John Wiley & Sons Ltd.
Chemical References
  • Antineoplastic Agents
  • BRCA2 Protein
  • BRCA2 protein, human
  • Phthalazines
  • Piperazines
  • Carboplatin
  • Paclitaxel
  • olaparib
Topics
  • Antineoplastic Agents (therapeutic use)
  • BRCA2 Protein (genetics)
  • Carboplatin (therapeutic use)
  • Cystadenocarcinoma, Serous (genetics)
  • Drug Resistance, Neoplasm (genetics)
  • Female
  • Germ-Line Mutation
  • Humans
  • Middle Aged
  • Neoplasm Recurrence, Local (drug therapy, genetics)
  • Ovarian Neoplasms (genetics)
  • Paclitaxel (therapeutic use)
  • Phthalazines
  • Piperazines
  • Polymerase Chain Reaction

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: